EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudieOpen Access · CC BY 4.0

Comparing survival outcomes between neoadjuvant and adjuvant chemotherapy within T2N1M0 stage hormone receptor-positive, HER2-negative breast cancer: a retrospective cohort study based on SEER database

Yuhang Shang, Xuelian Wang, Yansong Liu, Weilun Cheng, Yunqiang Duan, Zhengbo Fang, Jiangwei Liu, Fanjing Kong, Ting Wang, Tianshui Yu, Anbang Hu, Jiarui Zhang und 9 weitere

Breast Cancer · 2024-07 · 31 (4) · 684-694

DOI: 10.1007/s12282-024-01583-5 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Breast Cancer, online erschienen am 21.04.2024. Verfasst von Yuhang Shang und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150081, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoadjuvant Therapy, SEER Program, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Chongqing Xinqiao Hospital, Second Affiliated Hospital of Army Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Guideline recommendations for the application of neoadjuvant chemotherapy (NACT) in T2N1M0 stage hormone receptor-positive, HER2-negative (HR + /HER2-) breast cancer are ambiguous. The debate continues regarding whether NACT or adjuvant chemotherapy (ACT) offers superior survival outcomes for these patients. Materials and Methods Female patients diagnosed with HR + /HER2- breast cancer at T2N1M0 stage between 2010 and 2020, were identified from the Surveillance, Epidemiology, and End Results database and divided into two groups, the NACT group and the ACT group. Propensity score matching (PSM) was utilized to establish balanced cohorts between groups, considering baseline features. Kaplan–Meier (K-M) analysis and the Cox proportional hazards model were executed to assess the efficacy of both NACT and ACT in terms of overall survival (OS) and breast cancer-specific survival (BCSS). A logistic regression model was employed to examine the association between predictive variables and response to NACT.

Results

After PSM, 4,682 patients were finally included. K-M curves showed that patients receiving NACT exhibited significantly worse OS and BCSS when compared with patients undergoing ACT. Multivariable Cox analysis indicated that not achieving pathologic complete response (non-pCR) after NACT (versus ACT), was identified as an adverse prognostic factor for OS (HR 1.58, 95% CI 1.36–1.83) and BCSS (HR 1.70, 95% CI 1.44–2. 02). The logistic regression model revealed that low tumor grade independently predicted non-pCR.

Conclusion

Among T2N1M0 stage HR + /HER2- patients, OS and BCSS of NACT were inferior to ACT. Patients who attained non-pCR after NACT demonstrated significantly worse survival outcomes compared with those who received ACT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsNeoadjuvant TherapySEER ProgramErb-b2 Receptor Tyrosine KinasesReceptors, ProgesteroneHumansFemaleChemotherapy, AdjuvantMiddle AgedRetrospective StudiesAdultAgedNeoplasm StagingReceptors, EstrogenKaplan-Meier EstimatePropensity ScoreProportional Hazards Models

Stichwörter der Autor:innen

Adjuvant chemotherapyHormone receptor-positive breast cancerNeoadjuvant chemotherapySEER databaseSurvival outcomes

Substanzen

Erb-b2 Receptor Tyrosine KinasesReceptors, ProgesteroneReceptors, EstrogenERBB2 protein, human

Autor:innen und Institutionen

  • Department of General Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150081, China.
  • Department of General Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150081, China. baoliangguo2013@163.com.

Förderung

  • National Natural Science Foundation of China
  • Chongqing Xinqiao Hospital, Second Affiliated Hospital of Army Medical University

Zitieren

APA

Shang, Y., Wang, X., Liu, Y., Cheng, W., Duan, Y., Fang, Z., Liu, J., Kong, F., Wang, T., Yu, T., Hu, A., Zhang, J., Zhang, H., Li, M., Rong, Z., Li, Y., Shakila, S. S., Li, X., Feng, J., …, & Guo, B. (2024). Comparing survival outcomes between neoadjuvant and adjuvant chemotherapy within T2N1M0 stage hormone receptor-positive, HER2-negative breast cancer: a retrospective cohort study based on SEER database. Breast Cancer, 31(4), 684-694. https://doi.org/10.1007/s12282-024-01583-5

Vancouver

Shang Y, Wang X, Liu Y, Cheng W, Duan Y, Fang Z, et al. Comparing survival outcomes between neoadjuvant and adjuvant chemotherapy within T2N1M0 stage hormone receptor-positive, HER2-negative breast cancer: a retrospective cohort study based on SEER database. Breast Cancer. 2024;31(4):684-694. doi:10.1007/s12282-024-01583-5

BibTeX
@article{Shang2024,
  author = {Shang, Yuhang and Wang, Xuelian and Liu, Yansong and Cheng, Weilun and Duan, Yunqiang and Fang, Zhengbo and Liu, Jiangwei and Kong, Fanjing and Wang, Ting and Yu, Tianshui and Hu, Anbang and Zhang, Jiarui and Zhang, Hanyu and Li, Mingcui and Rong, Zhiyuan and Li, Yanling and Shakila, Suborna S and Li, Xinxin and Feng, Jianyuan and Ma, Fei and Guo, Baoliang},
  title = {Comparing survival outcomes between neoadjuvant and adjuvant chemotherapy within T2N1M0 stage hormone receptor-positive, HER2-negative breast cancer: a retrospective cohort study based on SEER database},
  journal = {Breast Cancer},
  year = {2024},
  volume = {31},
  number = {4},
  pages = {684--694},
  doi = {10.1007/s12282-024-01583-5}
}
Kostenlos starten →